NEW YORK (TheStreet) -- Hewlett-Packard (HPQ) said last week it's jumping into 3-D printing industry but that has had little effect on shares of Stratasys (SSYS) , up 6% over the past five trading sessions, Jim Cramer, the co-manager of the Action Alerts PLUS portfolio, said Monday.
He pointed out that analysts Piper Jaffray and JPMorgan both support Stratasys, downplaying the HP entry and reminding investors that HP won't begin shipping full orders until 2016.
Must Read: 12 Stocks Warren Buffett Loves in 2014
However, while "that's totally true," that still spells trouble for other 3-D printing stocks when HP starts "shipping in bulk," Cramer said on CNBC's "Cramer's Stop Trading" segment. In the meantime, Cramer sees shares of Stratasys going higher.
As for biotech stocks, Cramer noted Wells Fargo analyst Brian Abrahams' upgrade of BioMarin Pharmaceutical (BMRN) to outperform from market perform. Abrahams also boosted his price target to the range of $103 to $107 from $72 to $76.
"BioMarin is doing great things," Cramer said, as are Seattle Genetics (SGEN) and Isis Pharmaceuticals (ISIS) . These three companies could become the "heirs" to today's dominating biotech stocks, he said, referring to favorites Gilead Sciences (GILD) , Celgene (CELG) and Regeneron (REGN) .
The "junior" biotech stocks have the potential to become the "senior" biotech stocks, Cramer concluded, adding that he still likes Gilead, Celgene and Regeneron on the long the side.
-- Written by Bret Kenwell